Study guide
10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient
Key Takeaways Explain This Topic AI
CKD is staged by eGFR (G1 90 or above through G5 under 15 mL/min/1.73 m2) and albuminuria (A1 under 30, A2 30-300, A3 over 300 mg/g); cardiovascular death, not progression to dialysis, is the leading outcome in stages G3-G4.
Uremic pericarditis is a distinct indication for urgent intensified dialysis and typically lacks the diffuse ST elevation of viral pericarditis because uremic inflammation does not penetrate the myocardium.
The fistula or graft arm is protected absolutely: no blood pressure cuff, no venipuncture, no IV, no restraints; the nurse palpates for thrill and auscultates for bruit at least every shift.
Sotalol is contraindicated for atrial fibrillation when creatinine clearance is under 40 mL/min and dofetilide is contraindicated under 20 mL/min; apixaban is reduced to 2.5 mg twice daily when two of three criteria are met (age 80 or older, weight 60 kg or less, creatinine 1.5 mg/dL or higher).
A creatinine rise of up to 30% after starting a RAAS inhibitor or SGLT2 inhibitor is expected and is NOT a reason to stop the drug; avoid subclavian lines and PICCs in CKD to preserve veins for future dialysis access.
Last updated: August 2026
Staging and the Central Epidemiologic Fact
Test-plan item II.E.2 rests on one statistic that reframes everything: a patient with stage G3–G4 chronic kidney disease (CKD) is far more likely to die of cardiovascular disease than to reach dialysis. Cardiovascular mortality is roughly 10–30 times higher in dialysis patients than in the age-matched general population, and about half of all deaths on dialysis are cardiovascular. CKD is not a renal comorbidity in a cardiac patient — it is a coronary risk equivalent that also changes every drug dose you give.
CKD is defined as abnormalities of kidney structure or function present for more than 3 months , and is staged in two dimensions.
- eGFR stage eGFR (mL/min/1.73 m2) Albuminuria stage Urine albumin-to-creatinine ratio (mg/g)
- G1 90 or above (with kidney damage) A1 Under 30 (normal to mildly increased)
- G2 60–89 (with kidney damage) A2 30–300 (moderately increased)
- G3a 45–59 A3 Over 300 (severely increased)
- G3b 30–44
- G4 15–29
- G5 Under 15 or on dialysis
Both axes carry independent cardiovascular risk: a G3a/A3 patient is at higher risk than a G3b/A1 patient. Albuminuria is a marker of systemic endothelial dysfunction, which is why it tracks with cardiovascular events rather than just renal ones.
Uremic Cardiovascular Disease
Accelerated atherosclerosis driven by inflammation, oxidative stress, hyperphosphatemia, dyslipidemia and uremic toxins. Presentations are more often silent or atypical because of diabetic neuropathy and blunted symptom reporting.
Vascular and valvular calcification. CKD produces medial calcification (Monckeberg sclerosis) in addition to intimal plaque, producing stiff, non-compressible vessels, a wide pulse pressure, falsely elevated ankle-brachial indices, and accelerated calcific aortic stenosis — dialysis patients develop severe AS roughly a decade earlier than the general population.
Left ventricular hypertrophy from pressure load (hypertension, aortic stenosis, arterial stiffness) and volume load (anemia, arteriovenous fistula flow, salt and water retention). LVH plus small-vessel disease produces diastolic dysfunction, subendocardial ischemia with normal coronaries, and a heart that tolerates neither volume excess nor rapid volume removal.
Uremic pericarditis. A pericardial friction rub in a patient with a BUN typically above 60 mg/dL. Its ECG is characteristically atypical — often without the diffuse concave ST elevation and PR depression of viral pericarditis — because the uremic inflammatory process is confined to the pericardium and does not involve the epicardial myocardium. It is a distinct indication for urgent, intensified (often daily, heparin-free) dialysis , and it can progress to tamponade. Dialysis-associated pericarditis in an already-dialyzed patient signals inadequate dialysis dose.
CKD–mineral and bone disorder (CKD-MBD): phosphate retention, low calcitriol, secondary hyperparathyroidism, and in severe cases calciphylaxis — painful violaceous necrotic skin lesions with very high mortality.
Uremic platelet dysfunction producing a bleeding tendency at the access site, GI tract and pericardium despite a normal platelet count and INR; desmopressin, cryoprecipitate, conjugated estrogens and dialysis are the interventions.
Running a Dialysis Patient on a Cardiac Unit
Intradialytic hypotension complicates 20–30% of hemodialysis sessions and repeatedly produces myocardial stunning — transient regional wall motion abnormalities that, over months, become fixed and drive the cardiomyopathy of dialysis. Ultrafiltration rates above roughly 13 mL/kg/h are associated with excess mortality. The nurse's contributions are concrete: hold antihypertensives before dialysis when ordered, do not schedule an unnecessary sedating medication before a session, report symptomatic hypotension and cramping, and question a dry weight that the patient cannot tolerate.
Dry weight and interdialytic weight gain. Dry weight is the post-dialysis weight at which the patient is euvolemic without hypotension. Interdialytic weight gain is targeted below roughly 4–4.5% of body weight (about 2–3 kg over a two-day interval). Weigh the patient before and after every session on the same scale and report gains outside that range — they predict pulmonary edema, hypertension and LVH.
Potassium timing. Serum potassium is at its lowest immediately after a session and climbs across the interdialytic interval, peaking before the next one. The Monday morning arrest after a long weekend interval is the classic pattern. Draw potassium and check the ECG when a dialysis patient arrives, and interpret any level in relation to the last session.
Access rules — non-negotiable nursing content:
On the fistula or graft arm: no blood pressure cuff, no venipuncture, no IV catheter, no PICC, no tourniquet, no restraints, no lying on the arm, no constricting clothing. Post it at the bedside.
Assess thrill by palpation and bruit by auscultation at least every shift and after any hypotensive episode. A newly absent thrill is an emergency — the access has clotted and needs immediate intervention.
Watch for steal syndrome (cold, pale, painful, numb hand distal to the access) and for high-output heart failure from a very high-flow fistula.
Post-dialysis needle sites bleed; hold pressure without occluding the access, and remember uremic platelet dysfunction plus the heparin used during the session.
Tunneled dialysis catheters are accessed only by trained staff using strict aseptic technique, are locked with heparin or citrate, and are not used for routine blood draws or infusions without a specific order.
Vein preservation: in any patient with advanced CKD who is not yet on dialysis, avoid subclavian lines (central venous stenosis destroys future access options) and avoid PICCs entirely. Use the back of the hand for peripheral IVs and protect the non-dominant forearm.
Dialysis and drug levels. Many cardiac drugs are removed by dialysis and should be given after the session — a chronically under-recognized nursing failure. Water-soluble, low-protein-bound, low-volume-of-distribution drugs are dialyzed. Atenolol, sotalol, metoprolol (partially), lisinopril, enalapril, gabapentin, and many antibiotics are removed; carvedilol, amiodarone, digoxin (large volume of distribution — dialysis does not meaningfully remove it) and warfarin are not.